anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Interleukin-6 (IL-6) is a pro-inflammatory cytokine elevated in cytokine storm syndromes, including hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). It is also elevated in cytokine release syndrome (CRS) after immune activating cancer therapies such as chimeric antigen receptor (CAR) T-cells or bispecific T-cell engagers (BITEs) and in some patients after infection with SARS-CoV-2. The interaction of IL-6 with its receptor complex can happen in several forms, making effectively blocking this cytokine's effects clinically challenging. Fortunately, effective clinical agents targeting the IL-6 receptor (tocilizumab) and IL-6 directly (siltuximab) have been developed and are approved for use in humans. IL-6 blockade has now been used to safely and effectively treat several cytokine storm syndromes (CSS). Other methods of investigation in effective IL-6 blockade are underway.
<P>PROBLEM TO BE SOLVED: To provide an endoluminal stent and a stent graft including a graft.  <P>SOLUTION: This invention provides the stent graft. This releases an agent which induces the in vivo adhesion of the stent graft to vessel walls, or otherwise, induces or accelerates an in vivo fibrotic reaction which adheres this stent graft to the vessel wall. The method for producing such a stent graft and the use method are also provided. In a related aspect, the stent graft is constructed so that this graft itself is constituted of a material which induces adhesion to the vessel wall or fiber formation.  <P>COPYRIGHT: (C)2008,JPO&INPIT
After assessment of the tolerance of the drug during the single-blind period, during the which the starting dose of the drug of 100 mg b.i.d. should be increased after two weeks to the target dose 200 mg b.i.d, the patients will be randomized in 1:1 ratio to either intervention or placebo group. In the experimental arm, the patients after randomization will receive the dose 200 mg b.i.d of sacubitril/valsartan for the course of the study. If the patients does not tolerate the target dose of 200 mg b.i.d., the reduction of the drug dose to 100 mg b.i.d. will be possible at the discretion of the physician-in-charge.
A hardenable two part acrylic composition is described for the treatment of human or animal bone is described. The composition comprises a storage stable liquid first part and a storage stable liquid second part which react with each other upon mixing to form a cement which hardens. The composition further comprises an acrylic monomer component and an initiator component in an amount effective to polymerize the monomer component. The monomer component and the initiator component are generally located in separate parts of the two part composition so that the monomer component is storage stable. The liquid first part comprises emulsion polymerized acrylic polymer particles in a liquid carrier. A method of producing a hardenable two part acrylic composition is also described. The composition is particularly useful in a syringe or caulking gun having at least two barrels.
Technical solutions for classifying patients with respect to multiple cancer classes are provided. The classification can be done using cell-free whole genome sequencing information from subjects. A reference set of subjects is used to train classifiers to recognize genomic markers that distinguish such cancer classes. The classifier training includes dividing the reference genome into a set of non-overlapping bins, applying a dimensionality reduction method to obtain a feature set, and using the feature set to train classifiers. For subjects with unknown cancer class, the trained classifiers provide probabilities or likelihoods that the subject has a respective cancer class for each cancer in a set of cancer classes. The present disclosure thus describes methods to improve the screening and detection of cancer class from among several cancer classes. This serves to facilitate early and appropriate treatment for subjects afflicted with cancer.
PROBLEM TO BE SOLVED: To dissolve a platelet coagulating factor antagonist belonging to ginkgolide in an aqueous medium by forming an inclusion complex in water suing a specific cyclodextrin. SOLUTION: An antagonist is combined with a cyclodextrin of formula I [(n)=6-8; R<1> is OH or SR<2> (R<2> is a group derived from a monosaccharide or a polysaccharide)]. In formula I, R<2> is especially preferably a group of formula II [(p) is 0, 1-5]. As the antagonist, a ginkgolide of formula III (R<3> , R<5> and R<6> are each H or OH; R<4> is H, OH or a 1-5C alkoxy) is preferably included. An inclusion complex of the antagonist and a cyclodextrin of formula I is a new compound, and the complex can be used for a pharmaceutical composition in which a vehicle is pharmaceutically integrated. Forming of the inclusion complex of the antagonist enables the exhibition of high solubility in an aqueous medium at a biological pH while maximally remaining a closed ring state of the ginkgolide.
Interventional prospective, multicenter (8 dialysis units) , randomized, controlled, open study. Two strategies are compared in a parallel plan : a "valve arm " (implementation of TEGO ® valve associated with interdialytic saline locks) and a "control arm" ( standard care ). Rate of dialysis session with dysfunctions during the first six months of the study is the primary endpoint. It will be analyzed " per protocol ". The total duration of patient follow-up is 12 months.

After the first 6 months, patients in the "valve arm" retain the same type of care until the end of the study. The control patients continue to receive the usual concentrated heparin locks . The secondary endpoints of the study will be analyzed to 12 months. Training of health care teams is expected before the start of the study .
Participants will continue their current heart failure/ cardioprotective treatments. Participants will undergo clinical assessment at 6, 14 and 24 weeks and 6, 9 and 12 months with weight, blood pressure, and biomarker measurement. At baseline, 6- and 12-month visits detailed cardiovascular phenotyping using cardiovascular magnetic resonance scans and symptom and disutility questionnaires will be undertaken.
As a novel minimally invasive approach, microneedle-mediated transdermal drug delivery has received increased attention. Microneedle patch effectively penetrates the skin barrier of the stratum corneum and create efficient pathways for the delivery of drugs.

A randomized controlled trial based on split-body was planned to evaluate the efficacy of enhanced transdermal delivery of topical agent by hyaluronic acid (HA)-fabricated microneedle patch in psoriatic plaques. Six psoriatic plaques in a patient will be randomized to either microneedle HA patch, patch, or control groups. Patch group is planned for rule out the occlusion effect of patches. All lesions will be treated with topical agent and patches daily for 2-week period. The severity of psoriasis will be grated with modified PASI score and the clinical improvement will be assessed as % from baseline every week. Overall 20 patients with 120 psoriatic plaques will be enrolled.
Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
Non-neural extracellular matrix (ECM) has limited application in humanized physiological neural modeling due to insufficient brain-specificity and safety concerns. Although brain-derived ECM contains enriched neural components, certain essential components are partially lost during the decellularization process, necessitating augmentation. Here, it is demonstrated that the laminin-augmented porcine brain-decellularized ECM (P-BdECM) is xenogeneic factor-depleted as well as favorable for the regulation of human neurons, astrocytes, and microglia. P-BdECM composition is comparable to human BdECM regarding brain-specificity through the matrisome and gene ontology-biological process analysis. As augmenting strategy, laminin 111 supplement promotes neural function by synergic effect with laminin 521 in P-BdECM. Annexin A1(ANXA1) and Peroxiredoxin(PRDX) in P-BdECM stabilized microglial and astrocytic behavior under normal while promoting active neuroinflammation in response to neuropathological factors. Further, supplementation of the brain-specific molecule to non-neural matrix also ameliorated glial cell inflammation as in P-BdECM. In conclusion, P-BdECM-augmentation strategy can be used to recapitulate humanized pathophysiological cerebral environments for neurological study.
After initial presentation of our data concerning this regimen (in pancreatic cancer) at the 2003 and 2004 ASCO meetings, a number of practitioners began using the regimen for pancreatic cancer patients. More importantly, several of these investigators began using the same regimen for patients with unresectable and metastatic biliary tree cancers, such as cholangiocarcinoma. In personal communications with us, they have cited the absence of reasonable alternatives as the primary reason to experiment with novel regimens. They have described to us case reports, whereby patients with cholangiocarcinoma had objective responses to this regimen. Personally, our group, in a pilot study, has treated 5 patients with the GTX regimen, and has documented 3 partial responses and 1 stable disease in 3 patients afflicted with cholangiocarcinoma and 2 with gall bladder cancer. In this prospective study (to date 08/09), three patients have been enrolled and two of them achieved a partial response, by RECIST parameters, of \>30% reduction in tumor size by cycle 3 (the first evaluation point). Therefore, we believe that GTX will show efficacy in treating this disease.

Indeed, there is clinical evidence of efficacy of these drugs in cholangiocarcinomas. In a phase II trial, single agent gemcitabine produced a 30% partial response rate and a 30% stable disease rate in chemotherapy-naïve, cholangiocarcinoma patients.(8) A retrospective review of patients treated with combination fluorouracil (continuous infusion) and gemcitabine (30 minute infusion) demonstrated a 33% response rate and a 30% stable disease rate, with a median survival of 5.3 months. The low, observed rate of grade 3-4 myelosuppression (11%) suggests this is a well tolerated regimen.(9) Likewise, gemcitabine and docetaxel have been combined in the treatment of these cancers, resulting in a 33% response rate and a 36% stable disease rate (3). We hope to improve upon these studies by substituting a sixty minute infusion rate for gemcitabine instead of the traditional thirty minute infusion, and by substituting capecitabine for infused fluorouracil. In addition, we have tested the GTX regimen in 2 cell lines in our lab: one cholangiocarcinoma and one gall bladder human line. We found that when GTX is given all at once to the cells, there is no increased cytotoxicity, but when given in the amount and dosing sequence that mimics the GTX regimen of this protocol, there is significant synergistic cytotoxicity. This synergism produces approximately a 3-fold increase in cell kill as compared with any other combination of the drugs or from any single drug in the GTX regimen. Given our laboratory data in cholangiocarcinoma cell lines that demonstrates synergy between these drugs, we are optimistic that we can produce superior results with less toxicities.
Prior to the procedure, the patient will have two sets of two self-adhesive electrodes placed parallel to the spinal cord at the T10-L1 and S2-S4 levels for TENS administration. For participants randomized to the experimental group, the non-blinded study coordinator will turn on the TENS unit 5 minutes prior to the procedure and monitor stimulating frequency level (80-100 Hz and pulse duration of 400 microseconds; intensity or frequency will be monitored to be administered to a non-painful level).
PURPOSE:To obtain an anti-aids virus agent containing oxetanocin and salt thereof as an active ingredient, having high aids virus inhibiting effect and low toxicity and reduced in toxicity accumulation by continuous administration. CONSTITUTION:The aimed agent is obtained by using a compound expressed by the formula or salt thereof as active ingredient, as necessary blending the compound with a diluting agent or carrier and formulating the compound or blend according to ordinary method. The agent can be prepared into a form of injection, tablet, capsule, powder medicine, granule, liquid medicine, dry syrup, etc. The compound expressed by the formula in the agent is contained in an amount of usually 0.1-100wt.%, preferably 1-90wt.%. The agent contains 0.1-5wt.% compound in case of the injection or 3-100wt.%, preferably 5-90wt.% compound in case of the tablet, capsule, granule or powder and is administered in am amount of 1-300mg/kg . day parenterally or in an amount of 5-500mg/kg day orally.
Inclusion criteria in the experimental group are age 18-75 years old, colonoscopy revealing colon or rectal tumor, biopsy-confirmed adenocarcinoma or adenoma, no chemotherapy or surgery, and no history of other cancer. Both groups must be able to understand and be willing to sign informed consent.
One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
The efficacy of plant and animal active substances, especially hormones, regulatory factors, transmitters, enzymes, and of vitamins and trace elements is improved by binding them to polypeptides, peptides and/or nucleotides as carriers and additives which are obtained from microbial, plant and/or animal macromolecules by chemical hydrolysis or enzymatic degradation. Alkalisation of the loaded carriers and additives, also using trace elements and possibly surface-active substances, counteracts the environmental damage of the flora. It is also possible to use energy-transferring systems. "Tree death" resulting from difficulty in adapting to environmental changes is a preferred area of use, but also likewise the improvement of the utilisation and efficiency of feedstuffs and resistance to infections and stress in the rearing of productive livestock and the prophylaxis and therapy of damage from ionising radiation and cytotoxic substances. The efficacy of drugs in human and veterinary medicine is improved and protracted. The products are added to the nutrient media in bacteriology to stimulate the growth of microorganisms, and in tissue culture to improve the growth of cell cultures and to retain the specificity and the cell-division capacity.
BACKGROUND: The aim of this study was to assess the prognostic significance of lymph node yield (LNY), lymph node ratio (LNR), and the number of lymph node metastases (LNMs) in patients affected by oral squamous cell carcinoma (OSCC).
METHODS: The study included patients who underwent surgical treatment for primary OSCC. Receiver operating characteristic curves were generated to determine the optimal threshold values. Kaplan-Meier curves were employed, along with the log-rank test, for the analysis of survival. To compare the performance in terms of model fit, we computed Akaike's information criterion (AIC).
RESULTS: This study enrolled 429 patients. Prognostic thresholds were determined at 22 for LNY, 6.6% for LNR, and 3 for the number of LNMs. The log-rank test revealed a significant improvement in both overall survival and progression-free survival for patients with a LNR of ≤6.6% or a number of LNMs of ≤3 (p < 0.05). Interestingly, LNY did not demonstrate prognostic significance. The AIC analyses indicated that the number of LNMs is a superior prognostic indicator compared to LNY and LNR.
CONCLUSIONS: Incorporating LNR or the number of LNMs into the TNM classification has the potential to improve the prognostic value, as in other types of cancers. Particularly, the inclusion of the number of LNMs should be contemplated for future N staging.
Porphyromonas gingivalis is the major pathogenic bacteria found in the subgingival plaque of patients with periodontitis, which leads to neuroinflammation. The bacteria destroy periodontal tissue through virulence factors, which are retained in the bacteria's outer membrane vesicles (OMV). This study aimed to determine the real-time effect of an intraperitoneal injection of P. gingivalis OMV on the production and expression of inflammatory markers and histopathological changes in adult zebrafishes' central nervous systems (CNS). Following the LD50 (21 µg of OMV), the zebrafish were injected intraperitoneally with 18 µg of OMVs, and the control group were injected with normal saline at seven different time points. Brains of experimental zebrafish were dissected at desired time points for colorimetric assays, ELISA, and histology. This study discovered that nitric oxide and PGE2 were significantly increased at 45 min, while IL-1β and IL-6 were expressed at subsequent 12 h and 24 h time points, respectively. Histopathological changes such as blood coagulation, astrocytosis, edema, spongiosis, and necrosis were observed between the 6hour and 24 h time points. The two apoptotic enzymes, caspases 3 and 9, were not expressed at any point. In summary, the OMV-induced neuroinflammatory responses and histopathological changes in adult zebrafish were time-point dependent. This study will enrich our understanding of the mechanism of P. gingivalis OMVs in neuroinflammation in a zebrafish model, most especially the timing of the expression of inflammatory mediators in relation to observable changes in brain tissues.
A healthcare plan provider implements a method for providing a discount program to facilitate the purchase of pharmaceutical products by consumers. The plan provider enters into business relationships with companies that dispense pharmaceuticals to consumers, wherein, pursuant to the business relationships, the companies agree to provide discounts on purchases of pharmaceuticals to consumers displaying a predetermined discount card. The plan provider also engages at least one marketer to market the discount card to consumers. Responsive to information acquired from consumers by the marketer(s), the plan provider issues the predetermined discount card to each of the consumers. The plan provider, preferably using a software application running on a server or other processor, tracks a quantity of prescriptions purchased by the consumers through use of the issued discount cards. The plan provider then provides commissions to the marketer(s) based on the quantity of prescriptions purchased through use of the issued discount cards.
This is a study of self-reported stress in individuals with newly diagnosed breast cancer. Subjects will be randomized to either the standard of care (SOC) arm or the intervention arm. The principle investigators will be blinded to the arm assignment. The intervention utilized will be six weekly on-site GRT sessions. In addition, subjects will be provided with a CD utilizing a standardized GRT script and music for home use twice daily during the study period. During the intervention period, they will also be provided with a diary and required to keep a record of date and time of CD utilization at home. The subjects will also be required to record their stress level before and after each of the two home sessions. The sessions must be at least 4 hours apart.

The SOC arm will consist of an education session with the nurse or nurse practitioner and supportive care / symptom management as needed. This group will also be required to keep a daily diary in which they record their stress levels twice daily, at intervals separated by at least 4 hours.
The present invention discloses a Chinese medicinal plaster externally stuck to Ruzhong acupoint for treating spontaneous or night sweating, which is prepared from the following medicines according to weight percentage: 10 to 30% of Chinese gall, and 70 to 90% of curcuma root. The present invention is obtained through the following process: removing unwanted substance of the medicines, drying and pulverizing the medicines into fine powder which can pass through medicinal sieves No. 5 to 7; putting the fine powder of the medicines into a mortar, adding an adhesive and a skin penetrating agent, homogenizing and preparing into the paste with proper viscosity. The paste is used for treating common diseases, such as spontaneous sweating and night sweating. Patients neither need to take medicine, nor need to be injected. The present invention has the advantages of easy use and significant curative effects.
Naproxen sodium tablets, USP are nonsteroidal anti-inflammatory drugs and available as white capsule-shape tablets, containing 275 mg or 550 mg of naproxen sodium for oral administration.

Naproxen sodium is a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs. The chemical name for naproxen sodium is (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid, sodium salt. Naproxen sodium has a molecular weight of 252.25 and a molecular formula of C 14H 13NaO 3. It has the following structural formula: 

Naproxen is white to creamy crystalline powder. It is soluble in water and methanol, practically insoluble in chloroform, toluene and acetone, sparingly soluble in alcohol.

Each naproxen sodium tablet, USP contains the following inactive ingredients: hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, povidone, talc, and titanium dioxide.
The present invention discloses a traditional Chinese medicine compound preparation used for treating osteoporosis and a preparation method thereof. The present invention uses the following materials or extracts of the following materials as active ingredients, the extracts are extracted by alcohol, water or mixed liquor of the alcohol and the water, and the present invention is prepared from 400 to 1200g of prepared rehmannia root, 200 to 500g of yam, 50 to 600g of wolfberry fruit, 100 to 600g of eucommia bark, 50 to 650g of dodder seed, 50 to 380g of common curculigo rhizome, 40 to 350g of pilose asiabell root, 80 to 500g of milk vetch, 50 to 600g of red sage root, 30 to 400g of corydalis tuber processed with vinegar and 100 to 700g of calcined oyster. The extracts of the eleven raw materials are uniformly mixed, which are extracted by the alcohol, or the water or the mixed liquor of the alcohol and the water, and the required preparation type is prepared by adding proper auxiliary materials. The medicine performs the functions of nourishing the liver and the kidney, supplementing Qi and activating blood circulation. The present invention is used for symptoms of primary osteoporosis (symptom of insufficiency of the liver and the kidney), such as an aching whole body or the aching pelvic kidney, spasm of muscles and vessels, the limp, aching and hypodynamic lumbar spine, vertigo, dizziness, etc. The traditional Chinese medicine preparation has the advantages of exact curative effect, safe use and stable quality. The clinical test shows that the effective rate reaches 94%.